Track topics on Twitter Track topics that are important to you
WideCells Group plc (LON:WDC) has reached an “inflection” point that will see it “enter a new and significant period of growth”, the company’s founder and chief executive, João Andrade, will tell its annual meeting. He said revenues are now being received and are set to increase from both cell storage and research, and the stem cell insurance product, launching this month, will create a third income stream. Andrade will tell investors the business had made huge strides following its listing on AIM around a year ago. READ: The AGM presentation in full “Since this time, we have made astronomical progress in building a revenue generative end-to-end stem cell support services company,” he will say. “Testament to this is the recognition we received from DISRUPT 100, an annual index celebrating the businesses with the most potential to influence, change or create new global markets, where WideCells Group was ranked as the 21st most disruptive company globally. “This award is a great honour and I believe gives an indication of the huge impact our business is set to make on the medical world.” READ: Our Big Picture overview of WideCells
Original Article: WideCells Group at an inflexion point and primed for growthNEXT ARTICLE
Track and monitor developments in stem cell research and commercial development. Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry. BioPort...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...